A Phase 3 interventional study of Genotonorm and Genotonorm in Growth Disorders and Intrauterine Growth Retardation, sponsored by Pfizer. Completed at 30 sites in France. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2010-11-18.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Fetal Growth Retardation with a site in France — 8 open to participants now, 8 under way, 2 of them phase 3. Fetal Growth Retardation · France.
Among the 29 studies in Fetal Growth Retardation with a site in France, this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 1993, is one of 7 in phase 3, and was the 6th registered.
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
Browse Fetal Growth Retardation studies →8 of the 29 studies in Fetal Growth Retardation with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+ · Women only
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 5 mo · Healthy volunteers
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Women only
Central Hospital, Nancy, France · Sites in France
Ages 18–64 · Women only
University Hospital, Bordeaux · Sites in France
Ages 18+ · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.
This study: 3 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 1993.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.
Median enrollment 207 across the 16 interventional studies, 220 across the 13 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 29 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 2 studies filed under Fetal Growth Retardation — fewer than ten, so there is no comparison to draw.
2 of the studies in Fetal Growth Retardation with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05674487University Hospital, BordeauxProstaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN) | 2026-12-01 |
| NCT07864272University Hospital, Strasbourg, FranceAssessment of Invasive Genetic Testing in Fetuses With Isolated Intrauterine Growth Restriction Diagnosed After 28 Weeks of Gestation at Strasbourg University Hospitals (2016-2023) | 2026-12-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Fetal Growth Retardation with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
This study's enrollment of 208 is above the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.
Browse Fetal Growth Retardation studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Fetal Growth Retardation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Growth Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continuous 0.7 IU/kg/week or 0.03 mg/kg/day
Drug: Genotonorm
Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day
Drug: Genotonorm
Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day
Drug: Genotonorm
0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm
Annual growth rate was expressed as height velocity (centimeter \[cm\]/year). This was derived by substracting annual growth rate at Baseline from 2-year value. (Annual growth rate was calculated each year and rescaled to 1 year if the interval between x and x-1 was not 365 days, as long as a subject remains in the study): ANGRYx = (Height Yx - Height Y{x-1}) / {(Date of Yx - Date of Y{x-1}) /365.25}
Time frame: Baseline, 2 years
Annual Growth Rate Standard Deviation Score (SDS)
Calculated using Sempe reference means and standard deviations for growth rate according to age and sex. Standardization was performed for chronological age.
Time frame: Baseline, 1 to 6 years
Change From Baseline in Annual Growth Rate SDS
Calculated corresponding to the gender and chronological age by substracting annual growth rate SDS at Baseline from annual growth rate SDS at each year.
Time frame: Baseline, 1 to 3 years
Height (cm)
Performed by use of a wallmounted device (eg, Harpenden Stadiometer). Each subject was measured 3 times and the mean of these measurements was recorded as the present height. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.
Time frame: Baseline, 1 to 6 years, final height
Change From Baseline in Height (cm)
Calculated by substracting height at Baseline from height at each year. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.
Time frame: Baseline, 1 to 6 years, final height
Height (SDS)
Calculated using Sempe reference means and standard deviations for height. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.
Time frame: Baseline, 1 to 6 years, final height
Change From Baseline in Height (SDS)
Calculated by substracting height SDS at Baseline from height SDS at each year. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.
Time frame: Baseline, 1 to 6 years, final height
Body Mass Index (BMI)
BMI was calculated by weight divided by height squared.
Time frame: Baseline, 1 to 6 years
Weight
Time frame: Baseline, 1 to 6 years
Change From Baseline in Bone Age
Bone age was determined by the Greulich-Pyle method. Calculated by substracting bone age at Baseline from bone age at each year
Time frame: Baseline, 1 to 3 years
Change From Baseline in Bone Age/Change From Baseline in Chronological Age Ratio
Bone age was determined by the Greulich-Pyle method. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. Chronological Age used was the age at the date that the corresponding Bone Age X-ray was performed. Ratio was calculated by change from Baseline in bone age divided by change from Baseline in chronological age.
Time frame: 1 to 3 years
Chronological Age at Onset of Puberty
Chronological age (years) at first study visit with onset of puberty = (Date of study visit minus Date of Birth) divided by 365.25.
Time frame: Onset of puberty
Number of Subjects Reaching Puberty
The defined criteria for reaching puberty were: boy=if right or left testes volume ≥4 ml; girl=if breast development ≥2. Tanner Adolescent Pubertal Staging Questionnaire documents the stage of development of secondary sexual characteristics rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Onset of puberty was defined as the visit where the data recorded first met the above criteria for starting puberty.
Time frame: Baseline, 1 to 6 years
| Milestone | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Started | 68 | 71 | 69 |
| Received treatment | 68 | 70 | 68 |
| Completed | 6 | 4 | 8 |
| Not completed | 62 | 67 | 61 |
| Withdrew: Ongoing at cutoff date | 1 | 1 | 0 |
| Withdrew: Adverse event | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 4 | 9 |
| Withdrew: Other | 25 | 21 | 29 |
| Withdrew: Withdrawal by subject | 31 | 39 | 22 |
| Withdrew: Randomized but not treated | 0 | 1 | 1 |
Annual growth rate was expressed as height velocity (centimeter \[cm\]/year). This was derived by substracting annual growth rate at Baseline from 2-year value. (Annual growth rate was calculated each year and rescaled to 1 year if the interval between x and x-1 was not 365 days, as long as a subject remains in the study): ANGRYx = (Height Yx - Height Y{x-1}) / {(Date of Yx - Date of Y{x-1}) /365.25}
| cm/year | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm | 3.07 ± 2.21 | 3.97 ± 1.72 | 2.84 ± 1.71 |
Calculated using Sempe reference means and standard deviations for growth rate according to age and sex. Standardization was performed for chronological age.
| SDS | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Baseline (n=50, 42, 43) | -2.72 ± 1.83 | -2.58 ± 1.39 | -2.75 ± 1.73 |
| 1 year (n=57, 55, 59) | 2.14 ± 1.52 | 3.97 ± 2.26 | 1.71 ± 1.51 |
| 2 years (n=53, 49, 56) | 0.77 ± 1.57 | 2.00 ± 1.73 | 0.67 ± 1.22 |
| 3 years (n=39, 34, 41) | 0.36 ± 1.14 | 1.35 ± 1.78 | 0.31 ± 1.12 |
| 4 years (n=21, 18, 27) | 0.13 ± 1.55 | 0.61 ± 1.20 | 0.34 ± 1.20 |
| 5 years (n=12, 10, 20) | 0.18 ± 1.24 | 0.09 ± 0.88 | -0.02 ± 1.46 |
| 6 years (n=11, 7, 19) | 0.90 ± 1.92 | 0.59 ± 1.61 | 0.05 ± 1.20 |
Calculated corresponding to the gender and chronological age by substracting annual growth rate SDS at Baseline from annual growth rate SDS at each year.
| SDS | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| 1 year (n=49, 42, 42) | 4.81 ± 2.27 | 6.56 ± 2.55 | 4.37 ± 2.16 |
| 2 years (n=47, 37, 40) | 3.51 ± 2.50 | 4.53 ± 1.89 | 3.37 ± 2.33 |
| 3 years (n=34, 25, 32) | 3.31 ± 2.06 | 3.80 ± 2.20 | 3.17 ± 1.86 |
Performed by use of a wallmounted device (eg, Harpenden Stadiometer). Each subject was measured 3 times and the mean of these measurements was recorded as the present height. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.
| cm | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Baseline (n=58, 56, 60) | 105.22 ± 15.04 | 107.06 ± 12.29 | 106.44 ± 12.04 |
| 1 year (n=57, 55, 59) | 113.38 ± 15.09 | 116.31 ± 12.24 | 113.71 ± 12.01 |
| 2 years (n=53, 49, 56) | 119.67 ± 15.18 | 124.11 ± 13.02 | 120.64 ± 12.34 |
| 3 years (n=39, 34, 41) | 123.92 ± 15.08 | 131.75 ± 13.76 | 125.39 ± 12.52 |
| 4 years (n=21, 18, 27) | 124.67 ± 13.14 | 132.30 ± 13.23 | 127.59 ± 11.51 |
| 5 years (n=12, 10, 21) | 126.73 ± 10.01 | 131.01 ± 9.26 | 129.98 ± 9.93 |
| 6 years (n=11, 7, 20) | 133.29 ± 10.46 | 138.84 ± 8.69 | 135.45 ± 10.10 |
| Final height (n=17, 12, 22) | 146.86 ± 11.26 | 151.98 ± 6.52 | 149.13 ± 9.07 |
Calculated by substracting height at Baseline from height at each year. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.
| cm | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| 1 year (n=57, 55, 59) | 8.21 ± 1.38 | 9.21 ± 1.45 | 7.33 ± 1.32 |
| 2 years (n=53, 49, 56) | 14.77 ± 2.45 | 17.01 ± 2.21 | 13.92 ± 2.03 |
| 3 years (n=39, 34, 41) | 20.62 ± 3.00 | 24.49 ± 3.04 | 20.14 ± 2.78 |
| 4 years (n=21, 18, 27) | 26.36 ± 4.37 | 30.77 ± 3.43 | 25.83 ± 3.26 |
| 5 years (n=12, 10, 21) | 32.23 ± 5.92 | 35.70 ± 4.27 | 32.16 ± 3.81 |
| 6 years (n=11, 7, 20) | 38.20 ± 6.66 | 44.03 ± 3.09 | 38.01 ± 4.82 |
| Final height (n=17, 12, 22) | 45.39 ± 13.08 | 45.30 ± 13.72 | 40.93 ± 9.22 |
Calculated using Sempe reference means and standard deviations for height. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.
| SDS | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Baseline (n=58, 56, 60) | -3.16 ± 0.52 | -3.07 ± 0.46 | -3.21 ± 0.65 |
| 1 year (n=57, 55, 59) | -2.49 ± 0.54 | -2.17 ± 0.50 | -2.68 ± 0.69 |
| 2 years (n=53, 49, 56) | -2.21 ± 0.66 | -1.68 ± 0.52 | -2.38 ± 0.75 |
| 3 years (n=39, 34, 41) | -2.17 ± 0.70 | -1.38 ± 0.57 | -2.24 ± 0.90 |
| 4 years (n=21, 18, 27) | -2.16 ± 1.03 | -1.16 ± 0.73 | -2.09 ± 0.96 |
| 5 years (n=12, 10, 21) | -1.95 ± 1.26 | -1.15 ± 0.83 | -1.96 ± 1.10 |
| 6 years (n=11, 7, 19) | -1.80 ± 1.28 | -0.67 ± 0.66 | -1.93 ± 1.18 |
| Final height (n=14, 9, 18) | -2.06 ± 0.76 | -1.97 ± 0.95 | -2.29 ± 1.35 |
Calculated by substracting height SDS at Baseline from height SDS at each year. Final Height: Children are defined as reaching their final height when annual Growth Rate is less than 2 cm in the previous year and bone age is equal to or greater than 17 years in boys and equal to or greater than 15 years in girls.
| SDS | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| 1 year (n=57, 55, 59) | 0.67 ± 0.28 | 0.88 ± 0.30 | 0.53 ± 0.28 |
| 2 years (n=53, 49, 56) | 0.94 ± 0.45 | 1.40 ± 0.43 | 0.84 ± 0.37 |
| 3 years (n=39, 34, 41) | 1.06 ± 0.54 | 1.70 ± 0.54 | 0.99 ± 0.51 |
| 4 years (n=21, 18, 27) | 1.20 ± 0.81 | 1.98 ± 0.69 | 1.21 ± 0.54 |
| 5 years (n=12, 10, 21) | 1.37 ± 1.12 | 2.03 ± 0.87 | 1.46 ± 0.69 |
| 6 years (n=11, 7, 19) | 1.54 ± 1.12 | 2.60 ± 0.66 | 1.54 ± 0.86 |
| Final height (n=14, 9, 18) | 1.00 ± 0.53 | 0.97 ± 0.95 | 0.86 ± 1.16 |
BMI was calculated by weight divided by height squared.
| kg/m^2 | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Baseline (n=58, 56, 60) | 14.74 ± 1.48 | 15.14 ± 1.76 | 14.59 ± 1.51 |
| 1 year (n=56, 55, 59) | 14.82 ± 1.52 | 15.44 ± 1.94 | 14.87 ± 1.76 |
| 2 years (n=53, 49, 56) | 15.33 ± 1.78 | 15.92 ± 2.15 | 15.29 ± 2.00 |
| 3 years (n=39, 34, 41) | 15.59 ± 2.02 | 16.65 ± 2.92 | 15.58 ± 2.11 |
| 4 years (n=21, 18, 27) | 15.32 ± 1.56 | 17.03 ± 3.70 | 15.80 ± 2.37 |
| 5 years (n=12, 10, 21) | 15.80 ± 1.57 | 16.25 ± 1.70 | 16.69 ± 3.92 |
| 6 years (n=11, 7, 20) | 16.21 ± 1.46 | 16.34 ± 1.80 | 17.28 ± 4.21 |
| kg | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Baseline (n=58, 56, 60) | 16.77 ± 5.43 | 17.70 ± 5.12 | 16.79 ± 4.35 |
| 1 year (n=56, 55, 59) | 19.71 ± 6.28 | 21.29 ± 6.04 | 19.56 ± 5.17 |
| 2 years (n=53, 49, 56) | 22.66 ± 7.62 | 25.08 ± 7.43 | 22.64 ± 6.05 |
| 3 years (n=39, 34, 41) | 24.77 ± 8.80 | 29.61 ± 9.62 | 24.98 ± 7.05 |
| 4 years (n=21, 18, 27) | 24.30 ± 7.01 | 30.56 ± 10.42 | 26.28 ± 7.94 |
| 5 years (n=12, 10, 21) | 25.74 ± 6.22 | 28.07 ± 5.22 | 28.52 ± 8.96 |
| 6 years (n=11, 7, 21) | 29.13 ± 6.42 | 31.94 ± 7.28 | 32.30 ± 10.32 |
Bone age was determined by the Greulich-Pyle method. Calculated by substracting bone age at Baseline from bone age at each year
| Years | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| 1 year (n=53, 60, 56) | 1.17 ± 0.51 | 1.27 ± 0.72 | 1.25 ± 0.54 |
| 2 years (n=52, 51, 49) | 2.40 ± 0.90 | 2.50 ± 1.08 | 2.58 ± 0.97 |
| 3 years (n=41, 39, 35) | 3.53 ± 1.22 | 4.06 ± 1.05 | 3.67 ± 0.97 |
Bone age was determined by the Greulich-Pyle method. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. Chronological Age used was the age at the date that the corresponding Bone Age X-ray was performed. Ratio was calculated by change from Baseline in bone age divided by change from Baseline in chronological age.
| ratio | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| 1 year (n=53, 60, 56) | 0.96 ± 0.41 | 1.07 ± 0.62 | 1.06 ± 0.45 |
| 2 years (n=51, 51, 49) | 1.06 ± 0.41 | 1.14 ± 0.50 | 1.18 ± 0.44 |
| 3 years (n=35, 37, 35) | 1.09 ± 0.39 | 1.26 ± 0.32 | 1.14 ± 0.29 |
Chronological age (years) at first study visit with onset of puberty = (Date of study visit minus Date of Birth) divided by 365.25.
| Years | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Chronological Age at Onset of Puberty | 11.88 ± 2.22 | 11.12 ± 1.74 | 11.58 ± 1.42 |
The defined criteria for reaching puberty were: boy=if right or left testes volume ≥4 ml; girl=if breast development ≥2. Tanner Adolescent Pubertal Staging Questionnaire documents the stage of development of secondary sexual characteristics rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Onset of puberty was defined as the visit where the data recorded first met the above criteria for starting puberty.
| participants | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Baseline (Female, Not Started) | 25 | 31 | 39 |
| Baseline (Male, Not Started) | 43 | 39 | 29 |
| 1 year (Female, Not Started) | 24 | 27 | 37 |
| 1 year (Female, Started) | 1 | 3 | 2 |
| 1 year (Male, Not Started) | 36 | 35 | 27 |
| 1 year (Male, Started) | 4 | 3 | 1 |
| 2 years (Female, Not Started) | 20 | 20 | 31 |
| 2 years (Female, Started) | 3 | 7 | 6 |
| 2 years (Male, Not Started) | 31 | 28 | 20 |
| 2 years (Male, Started) | 9 | 7 | 6 |
| 3 years (Female, Not Started) | 16 | 10 | 16 |
| 3 years (Female, Started) | 3 | 9 | 11 |
| 3 years (Male, Not Started) | 19 | 15 | 9 |
| 3 years (Male, Started) | 6 | 7 | 4 |
| 4 years (Female, Not Started) | 10 | 7 | 10 |
| 4 years (Female, Started) | 2 | 5 | 7 |
| 4 years (Male, Not Started) | 10 | 5 | 7 |
| 4 years (Male, Started) | 1 | 2 | 3 |
| 5 years (Female, Not Started) | 5 | 4 | 5 |
| 5 years (Female, Started) | 2 | 3 | 10 |
| 5 years (Male, Not Started) | 6 | 6 | 4 |
| 5 years (Male, Started) | 2 | 1 | 1 |
| 6 years (Female, Not Started) | 3 | 3 | 3 |
| 6 years (Female, Started) | 3 | 2 | 12 |
| 6 years (Male, Not Started) | 5 | 4 | 1 |
| 6 years (Male, Started) | 3 | 1 | 4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Genotonorm 0.7 (Continuous Treatment) | — | 0/68 (0%) | 40/68 (58.8%) |
| Genotonorm 1.4 (Continuous Treatment) | — | 4/70 (5.7%) | 42/70 (60%) |
| Genotonorm 1.4 (Intermittent Treatment) | — | 3/68 (4.4%) | 35/68 (51.5%) |
| Event | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| TonsillectomySurgical and medical procedures | 0/68 | 4/70 | 3/68 |
| Event | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 19/68 | 19/70 | 12/68 |
| BronchitisInfections and infestations | 13/68 | 9/70 | 17/68 |
| NasopharyngitisInfections and infestations | 16/68 | 16/70 | 11/68 |
| Ear infectionInfections and infestations | 15/68 | 15/70 | 9/68 |
| GastroenteritisInfections and infestations | 4/68 | 8/70 | 11/68 |
| InfluenzaInfections and infestations | 6/68 | 9/70 | 7/68 |
| VaricellaInfections and infestations | 8/68 | 6/70 | 1/68 |
| PharyngitisInfections and infestations | 2/68 | 6/70 | 7/68 |
| RhinitisInfections and infestations | 4/68 | 2/70 | 6/68 |
| DiarrhoeaGastrointestinal disorders | 5/68 | 0/70 | 4/68 |
| Age, Customized(Participants) | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) | Total |
|---|---|---|---|---|
| < 4 years | 15 | 8 | 6 | 29 |
| 4 - 8 years | 29 | 32 | 29 | 90 |
| 8 - 12 years | 23 | 30 | 33 | 86 |
| >= 12 years | 1 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Genotonorm 0.7 (Continuous Treatment) | Genotonorm 1.4 (Continuous Treatment) | Genotonorm 1.4 (Intermittent Treatment) | Total |
|---|---|---|---|---|
| Female | 25 | 31 | 39 | 95 |
| Male | 43 | 39 | 29 | 111 |
The record gives a start of Jul 1993, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone